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Abstract
Background: Recent studies suggest that patients at greatest risk for diabetes complications are
least likely to self-monitor blood glucose. However, these studies rely on self-reports of
monitoring, an unreliable measure of actual behavior. The purpose of the current study was to
examine the relationship between patient characteristics and self-monitoring in a large health
maintenance organization (HMO) using test strips as objective measures of self-monitoring
practice.
Methods: This cross-sectional study included 4,565 continuously enrolled adult managed care
patients in eastern Massachusetts with diabetes. Any self-monitoring was defined as filling at least
one prescription for self-monitoring test strips during the study period (10/1/92–9/30/93). Regular
SMBG among test strip users was defined as testing an average of once per day for those using
insulin and every other day for those using oral sulfonylureas only. Measures of health status,
demographic data, and neighborhood socioeconomic status were obtained from automated
medical records and 1990 census tract data.
Results: In multivariate analyses, lower neighborhood socioeconomic status, older age, fewer
HbA1c tests, and fewer physician visits were associated with lower rates of self-monitoring.
Obesity and fewer comorbidities were also associated with lower rates of self-monitoring among
insulin-managed patients, while black race and high glycemic level (HbA1c>10) were associated
with less frequent monitoring. For patients taking oral sulfonylureas, higher dose of diabetes
medications was associated with initiation of self-monitoring and HbA1c lab testing was associated
with more frequent testing.
Conclusions: Managed care organizations may face the greatest challenges in changing the self-
monitoring behavior of patients at greatest risk for poor health outcomes (i.e., the elderly,
minorities, and people living in low socioeconomic status neighborhoods).
Background
Since the publication of the Diabetes Control and Com-
plications Trial results demonstrating the efficacy of in-
tense glycemic control using insulin therapy and frequent
self-monitoring of blood glucose (SMBG) in improving
health outcomes,[1] SMBG has become a principal
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component of diabetes management. While the efficacy of
self-monitoring independent of other self-management
practices is still uncertain, the practice is recommended
for patients using either insulin or oral drug therapy.[2] As
a result, managed care organizations (MCOs) are under
increasing pressure to cover the cost of self-monitoring
equipment[3] and to improve rates of SMBG among their
diabetes patients.[4]
In addition to logistic barriers to SMBG[5], some recent
evidence suggests that adult diabetes patients who may be
at greatest risk for poor outcomes (e.g., minorities, elderly,
lower SES) may be least likely to self-monitor.[4,6] In a
study of more than 44,000 managed care patients with
type 1 (2,818) and type 2 (41,363) diabetes, Karter et al[4]
identified older age, male gender, non-white race, lower
socioeconomic status, English language difficulty, higher
out of pocket test strip costs, intensity of insulin therapy,
greater alcohol consumption, and smoking as independ-
ent predictors of less frequent self-monitoring in diabetes
patients. This study was the first to move beyond simple
reporting of descriptive statistics in order to assess predic-
tors of SMBG in managed care settings. Unfortunately, the
validity of the study findings is limited by the reliance on
self-reports of self-monitoring, an unreliable measure of
actual behavior.[7]
The purpose of the current study was to examine the rela-
tionship between patient characteristics and SMBG in a
large health maintenance organization (HMO) using ob-
jective measures of self-monitoring practice. Specifically,
we tested the hypothesis that, controlling for type of drug
therapy and severity of illness, diabetes patients at greatest
risk for poor health outcomes (e.g., older age, multiple
chronic conditions, non-white race, lower neighborhood
SES) are less likely to practice SMBG. The study popula-
tion included more than 4,500 adult managed care pa-
tients using insulin, oral, or a combination of the two
drug therapies. Our use of objective measures of SMBG
distinguishes this study from previous attempts to identify
predictors of SMBG in managed care. This paper repre-
sents the first phase of a larger study to evaluate the effect
of distributing free home glucose monitors to diabetes pa-
tients at this New England HMO.
Methods
Study Setting and Data Sources
Harvard Vanguard Medical Associates (HVMA) is a multi-
specialty group practice serving nearly 300,000 people in
diverse ethnic and socioeconomic communities in and
around Boston, Massachusetts. At the time of the study,
nearly all of the patients at HVMA's fourteen health cent-
ers were insured in Harvard Pilgrim Health Care (HPHC),
one of the largest HMOs in New England. Home glucose
monitoring test strips were covered by HPHC and all
members had coverage for prescription medications. The
automated medical records system (AMRS) at HVMA/
HPHC captured data from all ambulatory and inpatient
encounters between plan members and providers in a
combination of both coded and narrative fields. The
AMRS has been previously used for research purpos-
es.[8,9] In addition to AMRS data, we mapped patients'
addresses to census tract information to control for the so-
cioeconomic characteristics of the patient's neighborhood
of residence.
Study Cohort
In order to be eligible for inclusion in the study, patients
had to be at least 18 years old and to have been diagnosed
with diabetes or to have received at least one prescription
for insulin or an oral sulfonylurea at some time between
December 1, 1991 and November 30, 1993. This study
represents the first phase in an evaluation of the imple-
mentation of a policy to provide free home glucose mon-
itors to HPHC patients. All data for this study were
collected from medical records covering the year preced-
ing the policy change (10/1/92–9/30/93). For continuity
of the study cohort, we included only those patients with
no more than 45 days disenrollment between 01/01/92
and 09/30/95. Patients with gestational diabetes were
excluded.
Dependent Variables
Our outcomes of interest were the likelihood of any SMBG
and regularity of SMBG once initiated. Patients were clas-
sified as having ever self-monitored if they filled at least
one prescription for self-monitoring test strips during the
study period. Test strip use has been employed in previous
studies as a reliable indicator of actual SMBG in diabetes
patients.[10–12] As only a very small number of patients
were using urine test strips to monitor glycemic levels
(1.5%), we did not include urine testing as a measure of
self-monitoring.
Regular SMBG among patients with any test strip use was
defined as filling prescriptions for 90 or more test strips
per quarter (i.e., testing an average of at least once per day)
for those using insulin or combination therapy, and 45 or
more per quarter (i.e., testing an average of at least once
every other day) for those using oral sulfonylureas only.
Cut points for regular use were based on dispensing pat-
terns and recent guidelines recommending testing three to
four times per day for insulin users and less frequent test-
ing for non-insulin users.[2] We assumed that test strips
were used evenly over the period between test strip dis-
pensings. Test strips were prorated over a minimum of 30
days if the next dispensing occurred sooner than that, and
over a maximum of 60 days if there was no subsequent
dispensing during that period. Multivariate analyses were
limited to patients using drug therapy and stratified byBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/6
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type of drug therapy (i.e., insulin alone or with sulfonylu-
reas, sulfonylureas only).
Independent Variables
We identified variables in the AMRS that represented fac-
tors that may influence preventive health behavior[13] as
well as those identified in the literature as being predictive
of SMBG.[4,6] Available demographic information in-
cluded gender, age, race, and Medicare or Medicaid insur-
ance status as recorded by the provider or health plan.
Given the small numbers of other minority groups at HV-
MA, we combined all racial groups other than white or
black into a single category labeled other. We then created
two dichotomous variables, black and other, with white
race as the reference group.
Census tract level data were used to represent the socioe-
conomic status of the patient and their neighborhood of
residence. We created an index composed of the sum of
four weighted census tract measures (i.e., percent with a
college education, median household income, percent of
households in which English was the primary language,
and percent home ownership). The variables included in
the index were standardized for summation by centering
them around a mean of zero. Their relative weightings in
the index were determined using factor analysis. Among
several measures created from census tract variables to
measure neighborhood SES, the index created using the
factor analysis approach proved to be the strongest predic-
tor of SMBG in univariate analyses.
Clinical assessments of health status as measures of sus-
ceptibility or potential for the threat of poor health out-
comes included two dichotomous measures of body mass
index[14] (i.e., overweight: 25 kg/m2 < BMI < 30 kg/m2;
obese: BMI ≥ 30 kg/m2) and an age- and gender-weighted
chronic disease score (CDS) [15] based on the presence or
absence of 29 specific comorbidities determined from
pharmacy dispensing data. In several HMO settings, the
CDS has performed as well or better than Ambulatory Dis-
ease Groups as a measure of illness severity, explaining
50–60% of variation in health care utilization, costs, and
mortality.[16] We included deciles of the CDS in multi-
variate regression analyses. We categorized the last record-
ed HbA1c test value for each individual into two
dichotomous measures representing poor and very poor
glycemic control (i.e., poor: HbA1c > 8.0%; very poor:
HbA1c > 10%), with HbA1c ≤ 8.0 as the reference group.
Average standard monthly dose of oral diabetes medica-
tion used was also included as an indicator of severity of
illness. These standardized measures were constructed by
first calculating median monthly dose of each drug type
received in the entire study cohort during the study peri-
od. The actual dose received in a month divided by this
median dose yielded a standardized monthly amount for
each patient. We then calculated the median of these pa-
tient-level standardized measures for the year and includ-
ed it as a covariate in the multivariate analyses.
Dichotomous variables representing the number of
HbA1c lab tests ( = 1 if # tests ≥ 2) and the number of phy-
sician visits ( = 1 if # visits ≥ 4) were included as measures
of predisposition to use health services. The HVMA prima-
ry care site, defined as the health center where at least 75%
of outpatient visits occurred (defined for 78% of pa-
tients), was included as a fixed effect to control for varia-
tions in practice patterns. As the vast majority of patients
(>96%) paid a $5 copayment for test strips during the
study period, cost to the patient was not included as a co-
variate of interest.
Statistical Analysis
Statistical analyses were carried out using SAS V8.04.[17]
All analyses were stratified by type of drug therapy (none,
insulin alone or in combination with oral sulfonylureas,
and oral sulfonylureas only) in accordance with the liter-
ature which suggests greater rates of monitoring among
those using insulin therapy.[18–20] We used chi-square
tests to compare baseline differences in demographic sta-
tus and health care utilization by type of drug therapy,
and in glycemic control by level of SMBG (e.g., none, any,
regular use). For patients using either form of drug thera-
py, we used logistic regression to estimate the factors asso-
ciated with the likelihood of initiating SMBG and
regularity of SMBG for those with some test strip use. We
first examined the univariate relationships between each
candidate predictor and our two SMBG outcomes. Age,
gender, chronic disease score, the number of HbA1c tests,
and primary care location were controlled for in all mod-
els. Other variables were included in the multivariate
models if univariate p-values fell below 0.20. We used
backward selection to remove variables not significant at
the .05 level. Overall model fit, including the necessity for
interaction terms, was ascertained using likelihood ratio
statistics.[21] Tests of mixed (i.e., hierarchical or random
effects) models,[22] where census tract was defined as a
higher-level random effect, produced no evidence of clus-
tering at the census tract level, indicating that the fixed ef-
fects approach was adequate.
Results
Characteristics of the Sample
The total study sample consisted of 4,565 patients, among
whom 30% used no drug therapy, 31% used insulin ther-
apy alone or in combination with oral agents, and 39%
were taking only oral sulfonylureas. The study cohorts de-
fined by type of therapy varied considerably with respect
to several important demographic and clinical character-
istics. Compared to those using drug therapy, the non-BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/6
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drug therapy group was more likely to be female (55% vs.
47%; p < 0.001), white (76% vs. 67%: p < 0.001), and to
have no comorbidities (33% vs. 2%; p < 0.001). As shown
in Table 1, insulin-managed patients were more likely to
be female (51% vs. 44%, p < 0.001), of younger average
age (51 vs. 56; p < 0.001), and Black (31% vs. 25%; p <
0.001) compared to those using sulfonylureas. They were
also less likely to be enrolled in Medicare (17% vs. 24%;
p < 0.001), which was consistent with the differences in
age. While sulfonylurea-managed patients were more like-
ly to be obese (55% vs. 46%; p < 0.001), insulin patients
had a higher number of comorbidities, on average, than
either the sulfonylurea only or the no drug group (3.1 vs.
2.8 vs. 1.6; respectively; p < 0.001 in both group compar-
isons). There were no significant (p < 0.05) differences in
neighborhood SES by type of drug therapy.
As shown in Table 2, insulin-managed patients had more
health center visits on average (14.2 ± 11.9) than those us-
ing either oral (10.7 ± 8.5) or no drug therapy (10.1 ±
8.8); this difference was statistically significant (p <
0.001). Compared to sulfonylurea-managed patients, in-
sulin-managed were more likely to have been hospitalized
during the study period (20% vs. 13%; p < 0.001) and to
have had an emergency room visit (25% vs. 17%; p <
0.001).
SMBG, Lab Testing, and Glycemic Control
SMBG frequency was well below recommended guide-
lines for both insulin and sulfonylurea patients (Table 2).
Insulin-managed patients were more likely to self-moni-
tor compared to those using oral medications (66% vs.
24%; p < 0.001). However, regular SMBG was far less
prevalent among insulin-managed and sulfonylurea-
managed patients (22% vs. 7% respectively, p < 0.001).
Only 7% of patients managed without drugs used any test
strips during the year.
Table 1: Demographic and Clinical Characteristics of Diabetes Cohort and Drug Treatment Categories*,†
Managed Without Drugs (n = 1,346) Insulin-Managed (n = 1,428 Oral Sulfonylurea-Managed (n = 1,791)
Characteristics N (%) N (%) N (%)
Gender
Male 600 (44.6) 697 (48.8) 1,003 (56.0)
Female 746 (55.4) 731 (51.2) 788 (44.0)
Mean Age 52 ± 14.2 51 ± 14.1 56 ± 12.3
Race N (%) N (%) N (%)
White 747 (75.5) 652 (65.6) 814 (68.5)
Black 180 (18.2) 305 (30.7) 300 (25.2)
Other 62 (6.3) 37 (3.7) 75 (6.3)
Missing 357 --- 434 --- 602 ---
Eligibility
Medicaid 17 (1.3) 10 (0.7) 7 (0.4)
Medicare 238 (17.8) 242 (17.2) 420 (23.7)
Commercial 1,079 (80.9) 1,159 (82.1) 1,345 (75.9)
Missing 12 --- 17 --- 19 ---
Body Mass 
Index‡
Underweight 13 (1.2) 13 (1.1) 11 (0.8)
Normal 220 (19.5) 249 (21.2) 201 (13.9)
Overweight 370 (32.8) 377 (32.0) 441 (30.4)
Obese 525 (46.5) 538 (45.7) 797 (55.0)
Missing 218 --- 251 --- 341 ---
Comorbidities
None 444 (33.0) 27 (1.9) 45 (2.5)
1–2 570 (42.4) 628 (44.0) 837 (46.7)
3–4 250 (18.6) 446 (31.2) 626 (35.0)
5 or More 82 (6.1) 327 (22.9) 283 (15.8)
Avg # of 
Comorbidities
1.57 ± 1.62 3.12 ± 2.06 2.83 ± 1.73
* All percentages are calculated for those with non-missing data. †All differences between characteristics for the insulin-managed and oral sulfonylu-
rea managed groups were significant at the 0.02 level (p < 0.01). ‡ For the Body Mass Index(BMI) variable: underweight = BMI ≤ 18.5 kg/m2, normal 
= 18.6 < BMI < 25 kg/m2, overweight = 25.0 ≤ BMI < 30.0 kg/m2, and obese = BMI ≥ 30 kg/m2BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/6
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Approximately 77% of drug therapy patients had at least
one HbA1c lab test per year. In contrast, fewer than half of
patients managed without drugs were tested (48%, p <
0.001). Among patients with at least one lab test, insulin-
managed patients had higher average HbA1c levels (8.9%
test value ± 1.7%) compared to sulfonylurea-managed
(8.3% ± 1.7%) and non-drug managed (7.1% ± 1.3%) pa-
tients (p < 0.001 for both comparisons). Over half (58%)
of all patients on drug therapy who were tested had at
least one HbA1c value greater than 8.0% during the study
period and 17% of those not on drug therapy who were
tested had similarly elevated glycemic levels (p < 0.01).
There were no significant differences in glycemic level by
level of SMBG for those without any drug therapy and for
patients using sulfonylureas. However, for the insulin-
managed group, patients who monitored regularly were
much less likely to be in very poor control (14% with
HbA1c > 10%) compared to patients with no test strip use
(31%) or with irregular test strip use (32%) (p < 0.001 for
both comparisons).
Predictors of SMBG
Results of the multivariate analyses examining the likeli-
hood of any SMBG are presented in Table 3. For insulin-
managed patients, higher SES of the census tract was sig-
nificantly associated with greater odds of SMBG (Odds
Ratio: 1.41; 95% Confidence Interval: 1.18–1.70) as hy-
pothesized. Further, older age (OR: 0.80; CI: 0.70–0.91),
male gender (OR: 0.69; CI: 0.52–0.90), and obesity
(OR:0.64; CI:0.44–0.95) were significantly associated
with lower odds of SMBG. However, higher level of co-
morbidity was associated with greater odds of SMBG, an
effect that ran counter to our hypothesis (OR: 1.63; CI:
1.21–2.20). Two or more laboratory HbA1c tests (OR:
1.60; CI: 1.19–2.14) and four or more physician visits
(OR: 1.80; CI: 1.16–2.81) were also significant correlates
of SMBG.
As in the insulin-managed group, higher SES of the census
tract was significantly associated with greater odds of any
SMBG among patients using oral sulfonylureas (OR: 1.26;
CI: 1.07–1.47). Older age (OR: 0.85; CI: 0.76–0.96) was
associated with lower odds of SMBG. Two or more HbA1c
tests (OR: 1.45; CI: 1.14–1.86), four or more physician
visits (OR: 2.06; CI: 1.40–3.01), and the standard month-
ly dose of diabetes medications (OR: 1.13; CI: 1.04–1.23)
were associated with greater odds of SMBG in the oral
managed group.
Predictors of Regularity of SMBG
The only factors significantly associated with regular
SMBG for the insulin-managed group were black race
Table 2: Forms of Health Service Use Among the Diabetes Cohort by Drug Treatment Categories
Managed Without Drugs (n = 1,346) Insulin-Managed (n = 1,428) Oral Sulfonylurea-Managed (n = 1,791)
Health Service Use 
Characteristics
Mean Visits† % 1+ Visit Mean Visits % 1+ Visit Mean Visits % 1+ Visit
Total Health Center Visits* 10.1 ± 8.8 (95.9) 14.2 ± 11.9 (97.5) 10.7 ± 8.5 (97.5)
Scheduled 8.8 ± 8.1 (94.1) 12.7 ± 10.9 (96.9) 9.6 ± 7.8 (96.5)
Same Day or Urgent 1.3 ± 1.8 (58.6) 1.6 ± 2.2 (62.0) 1.2 ± 1.7 (56.8)
Specialist Visits 
(Endocrinology)
0.07 ± 0.46 (3.1) 0.22 ± 0.96 (8.1) 0.05 ± 0.39 (2.7)
Total Emergency Room† 0.23 ± 0.63 (16.1) 0.43 ± 1.0 (25.3) 0.26 ± 0.72 (17.0)
Total Hospitalizations 0.17 ± 0.49 (13.1) 0.31 ± 0.77 (20.2) 0.19 ± 0.56 (13.2)
Diabetes Medications‡
Avg # Dispensing per Yr --- 7.3 ± 3.9 5.5 ± 3.5
Avg Standard Monthly Dose 
(SMD)
--- 1.3 ± 0.93 1.4 ± 1.3
Self-Monitoring Blood Glucose
Any (1+ Test Strip) 97 (7.2) 936 (65.6) 431 (24.1)
Regular§ N/A N/A 320 (22.4) 123 (6.9)
Completed HbA1c Tests||
Avg # HbA1c Tests per Yr 1.7 ± 0.9 2.2 ± 1.4 2.1 ± 1.3
Total # HbA1c Tests
0 705 (52.4) 317 (22.2) 418 (23.3)
1 362 (26.9) 430 (30.1) 554 (30.9)
2 177 (13.2) 315 (22.1) 389 (21.7)
3+ 102 (7.6) 366 (25.6) 430 (24.0)
* Based on AMRS records and includes face-to-face visits. † ER visits include those leading up to a hospitalization. ‡ Based on pharmacy dispensing 
data. Oral sulfonylurea-managed medication includes acetohexamide, chlorpropamide, glipizide, glyburide, tolazamide, and tolbutamide. §Regular 
self-monitoring of blood glucose is defined as 90 strips/quarter for those using insulin and 45 strips/quarter for those using oral sulfonylureas. || 
HbA1c test results reported only for those with at least one test. Managed without drugs n = 641; with insulin = 1,111; with oral sulfonylureas n = 
1,373.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/6
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(OR: 0.46; CI: 0.26–0.81) and very poor glycemic control
(OR: 0.38; CI: 0.21–0.69). The only covariate identified as
a significant predictor of regular SMBG in the sulfonylu-
rea-managed group was having two or more HbA1c tests
(OR: 1.89; CI: 1.18–3.04). The lack of significant predic-
tors of regular SMBG for patients managed with sulfony-
lureas may be due to the small proportion (7%) of regular
users in this group.
Discussion
Our findings suggest that managed care patients who may
benefit the most from intensive diabetes management
may be least likely to self-monitor blood glucose. Among
insulin users, older age and lower neighborhood SES were
associated with lower odds of any SMBG. Further, black
race and lack of glycemic control were significantly associ-
ated with less frequent SMBG, suggesting that these char-
acteristics may represent significant barriers to adherence.
For patients using oral medications, older age and lower
neighborhood SES were also associated with lower odds
of initiating SMBG.
Our findings for lower SES, older age, and black race were
consistent with those of other studies.[4–6] In contrast to
our hypothesis, having multiple comorbidities was associ-
ated with higher odds of any SMBG for the insulin group.
However, this result may be consistent with sicker patients
being urged to monitor more frequently. There was no ev-
idence to suggest that glycemic level was associated with
SMBG except for patients using insulin. Among this
group, lack of glycemic control (e.g., HbA1c > 10.0) was
associated with less than half the odds of frequent SMBG.
In a recent study using data from the third National
Health and Nutritional Examination Survey (1988–
1994), Harris[18] found no association between glycemic
levels and SMBG controlling for type of drug therapy.
There are several limitations to this study which merit dis-
cussion. Most importantly, the cross sectional nature of
the study design prevents us from drawing causal infer-
ences about the relationship between the chosen covari-
ates and SMBG behavior. For example, the association
between glycemic control and SMBG could suggest either
that sicker patients are less likely to practice SMBG or that
patients who practice SMBG are more likely to be in glyc-
emic control. Furthermore, as most states now mandate
coverage of home monitoring equipment, the impact of
variations in coverage of test strips, which may cost the pa-
tient more than the monitor in the long run, may be a
more relevant topic for future studies. Also, more evidence
of the efficacy of SMBG for patients with Type 2 diabetes
is needed, especially given the potential importance of be-
lief in the efficacy of SMBG on patient behavior. [13]
The policy to cover the cost of home glucose monitors at
this HMO was implemented in anticipation of the DCCT
results. In further analyses of the policy, we found that the
barriers to SMBG identified in this study did not change
over time. Further, the rate of SMBG changed very little
pre- and post-release of the DCCT findings and the policy
change at HPHC. Lastly, similarities between our results
and those from more recent studies of diabetes self-man-
Table 3: Predictors of Any and Regular Self-Monitoring of Blood Glucose (SMBG) by Drug Treatment Categories*
Any SMBG Regular SMBG†
Insulin-Managed Sulfonylurea-Managed Insulin-Managed Sulfonylurea-Managed
Predictors OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI]
Age (in units of 10 yrs) 0.80 [0.70,0.91] 0.85 [0.76,0.96] 0.88 [0.73, 1.05] 1.02 [0.82, 1.28]
Male 0.69 [0.52, 0.90] 0.90 [0.71, 1.14] 0.88 [0.59, 1.32] 1.00 [0.64, 1.56]
Chronic Disease Score (Deciles) 1.63 [1.21,2.20] 0.97 [0.91,1.03] 1.07 [0.97, 1.19] 1.08 [0.97, 1.21]
Total # HbA1c Tests (≥ 2) (Y/N) 1.60 [1.19, 2.14] 1.45 [1.14, 1.86] 1.09 [0.71, 1.66] 1.89 [1.18, 3.04]
Socioeconomic Status (SES)‡ 1.41 [1.18, 1.70] 1.26 [1.07, 1.47] 1.25 [0.95, 1.64] --
Total # Physician Visits (≥ 4) (Y/N) 1.80 [1.16, 2.81] 2.06 [1.40, 3.01] -- --
Standard Monthly Dose -- 1.13 [1.04, 1.23] -- --
Black Race (vs. White Race) -- -- 0.46 [0.26,0.81] --
Other Race (vs. White Race) -- -- 0.32 [0.09,1.23] --
Overweight§ (vs. BMI ≤ 24.9 kg/m2) 0.90 [0.61,1.35] -- -- --
Obese§ (vs. BMI ≤ 24.9 kg/m2) 0.64 [0.44,0.95] -- -- --
Poor Control§ (vs. HbA1c ≤ 8.0) -- -- 0.83 [0.53,1.29] --
Very Poor Control§ (vs. HbA1c ≤ 
8.0)
-- -- 0.38 [0.21,0.69] --
*For all multivariate logistic regression models, ORs (Odds Ratios) were adjusted for differences among primary health centers. Significant predic-
tors are in bold. †Regular self-monitoring was defined as 90 or more test strips per quarter (i.e., testing an average of at least once per day) for 
those using insulin therapy, and 45 or more per quarter (i.e., testing an average of at least once every other day) for those using oral sulfonylureas 
only. ‡Socioeconomic Status is represented by an index based on education, income, language, home ownership in the census tract of residence. 
§Overweight = 30 kg/m2 > BMI ≥ 25 kg/m2; Obese = BMI ≥ 30 kg/m2; Poor Control = 8.0 < HbA1c ≤ 10.0; Very Poor Control = HbA1c > 10.0.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/6
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agement would lend additional support to our conclu-
sions regarding SMBG.
Test strip dispensings are not a perfect measure of actual
use, but are likely to be more objective than self-reports.
Also, failure to control for individual SES may have caused
us to overestimate the effect of neighborhood SES. [24–
26] Still, other studies have found a significant effect of
neighborhood SES on individual health and mortality
even when individual-level SES was controlled for in the
analyses. [27–32] Using an index similar to our own, Diez
Roux et al[32] recently found that living in a relatively dis-
advantaged neighborhood was associated with greater in-
cidence of coronary heart disease among whites, even
after adjusting for individual-level SES (Hazard Ratio: 1.6;
95% CI: 1.1–1.2).
Missing data may have introduced bias into our results. In
particular, we only included patients who were continu-
ously enrolled, thereby limiting the generalizability of our
study to continuously enrolled managed care patients
with diabetes. Further, approximately 22% of the study
population did not receive an HbA1c test during the study
period, and we anticipate that patients with lower average
HbA1c levels were less likely to have had a lab test. Race
data were unavailable for 31% of the study population.
However, in a comparison of race data from the AMRS to
member self-reports, it was found that blacks were only
slightly more likely to be incorrectly categorized (2% of
blacks vs. 0% of whites) or counted as missing (38% of
blacks vs. 32% of whites) relative to whites (unpublished
data, Choo P, Platt R).
Data on duration of diabetes and type of diabetes, which
Karter et al[4] identified as predictors of SMBG adherence,
were not consistently available in the AMRS. Therefore,
we controlled for severity of illness using type and inten-
sity of drug therapy, the number of comorbidities,
glycemic level, and health service use. Still, it is possible
that the association of younger age with higher likelihood
of SMBG may in part reflect differences in type or duration
of diabetes among insulin users.
The greatest strength of our study is the use of more objec-
tive measures of SMBG. Data on test strips are less vulner-
able to response biases that may hinder the detection of
important relationships. Furthermore, the structure of the
pharmacy benefit at the time of our study makes it very
likely that all test strip dispensings would occur in health
plan pharmacies. While our data were gathered from one
HMO, the large and diverse patient population at HPHC
increases the generalizability of our results to other man-
aged care settings.
Conclusions
While the efficacy of SMBG has yet to be demonstrated,
MCOs are under increasing pressure to cover the cost of
SMBG equipment for their patients and to improve rates
of SMBG. Our findings provide troubling evidence that
MCOs may face the greatest challenges in changing the
self-monitoring behavior of the patients at greatest risk for
poor health outcomes. Concern over health disparities
has drawn increased attention toward community-based
interventions for diabetes. Results of ongoing interven-
tions may provide managed care organizations with use-
ful strategies for reaching the groups most at risk for poor
diabetes outcomes. In addition, well-controlled longitu-
dinal studies of the relationship between the factors iden-
tified in this study and patterns of SMBG and self-
management more generally can inform future
interventions.
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